1
|
Vidal M, Gérard A, Floquet V, Forthomme J, Christensen JB, Almhagen E, Grusell E, Heymans V, Rossomme S, Dumas S, Trimaud R, Hérault J. Beam monitor chamber calibration of a synchro-cyclotron high dose rate per pulse pulsed scanned proton beam. Phys Med Biol 2024; 69:085016. [PMID: 38252970 DOI: 10.1088/1361-6560/ad2123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 01/22/2024] [Indexed: 01/24/2024]
Abstract
Objective. Ionization chambers, mostly used for beam calibration and for reference dosimetry, can show high recombination effects in pulsed high dose rate proton beams. The aims of this paper are: first, to characterize the linearity response of newly designed asymmetrical beam monitor chambers (ABMC) in a 100-226 MeV pulsed high dose rate per pulse scanned proton beam; and secondly, to calibrate the ABMC with a PPC05 (IBA Dosimetry) plane parallel ionization chamber and compare to calibration with a home-made Faraday cup (FC).Approach. The ABMC response linearity was evaluated with both the FC and a PTW 60019 microDiamond detector. Regarding ionometry-based ABMC calibration, recombination factors were evaluated theoretically, then numerically, and finally experimentally measured in water for a plane parallel ionization chamber PPC05 (IBA Dosimetry) throughkssaturation curves. Finally, ABMC calibration was also achieved with FC and compared to the ionometry method for 7 energies.Main results. Linearity measurements showed that recombination losses in the new ABMC design were well taken into account for the whole range of the machine dose rates. The two-voltage-method was not suitable for recombination correction, but Jaffé's plots analysis was needed, emphasizing the current IAEA TRS-398 reference protocol limitations. Concerning ABMC calibration, FC based absorbed dose estimation and PPC05-based absorbed dose estimation differ by less than 6.3% for the investigated energies.Significance.So far, no update on reference dosimetry protocols is available to estimate the absorbed dose in ionization chambers for clinical high dose rate per pulse pulsed scanned proton beams. This work proposes a validation of the new ABMC design, a method to take into account the recombination effect for ionometry-based ABMC calibration and a comparison with FC dose estimation in this type of proton beams.
Collapse
Affiliation(s)
- Marie Vidal
- Institut Méditerranéen de Protonthérapie-Centre Antoine Lacassagne, Fédération Claude Lalanne, Nice, France
| | - Anaïs Gérard
- Institut Méditerranéen de Protonthérapie-Centre Antoine Lacassagne, Fédération Claude Lalanne, Nice, France
| | - Vincent Floquet
- Institut Méditerranéen de Protonthérapie-Centre Antoine Lacassagne, Fédération Claude Lalanne, Nice, France
| | | | - Jeppe Brage Christensen
- DTU Health Tech, Technical University of Denmark, Roskilde, Denmark
- Department of Radiation Safety and Security, Paul Scherrer Institute, PSI Villigen, Switzerland
| | - Erik Almhagen
- Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medical Radiation Science-Skandion Clinics Uppsala, Sweden
| | - Erik Grusell
- Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medical Radiation Science-Skandion Clinics Uppsala, Sweden
| | | | | | - Serge Dumas
- Institut Méditerranéen de Protonthérapie-Centre Antoine Lacassagne, Fédération Claude Lalanne, Nice, France
| | - Richard Trimaud
- Institut Méditerranéen de Protonthérapie-Centre Antoine Lacassagne, Fédération Claude Lalanne, Nice, France
| | - Joël Hérault
- Institut Méditerranéen de Protonthérapie-Centre Antoine Lacassagne, Fédération Claude Lalanne, Nice, France
| |
Collapse
|
2
|
Grandvillain M, Vidal M, Hérault J, Benabdesselam M, Hofverberg P, Mady F. Silica-based scintillators: basic properties of radioluminescence kinetics. J Phys Condens Matter 2024; 36:245701. [PMID: 38447159 DOI: 10.1088/1361-648x/ad3094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 03/06/2024] [Indexed: 03/08/2024]
Abstract
Radioluminescent silica-based fiber dosimeters offer great advantages for designing miniaturized realtime sensors for high dose-rate dosimetry. Rise and fall kinetics of their response must be properly understood to better assess their performances in terms of measurement speed and repeatability. A standard model of radioluminescence (RL) has already been quantitatively validated for doped silica glasses, but beyond conclusive comparisons with specific experiments, a comprehensive understanding of the processes and parameters determining transient and equilibrium kinetics of RL is still lacking. We analyze in detail the kinetics inherent in the standard RL model. Several asymptotical regimes in the RL growth are demonstrated in the case of a pristine sample (succesive quadratic, linear and power-law time dependencies before the plateau is reached). We show how this situation is modified when a pre-irradiation partly fills traps beforehand. RL growth is then greatly accelerated because of the pre-formation of recombination centers (RCs) from dopant ions, but not due to pre-filling of trapping levels. In all cases, the RL intensity eventually tends to a constant level equal to the pair generation rate, long before all carrier densities themselves reach equilibrium. This occurs late under irradiation, when deep traps get to saturation. The fraction of dopants converted into RCs is then 'frozen' at a lower level the smaller the density of deep traps. Controlling RL kinetics through the engineering of material traps is not an option. Pre-irradiation appears to be the simplest way to obtain accelerated and repeatable kinetics.
Collapse
Affiliation(s)
- Marjorie Grandvillain
- Université Côte d'Azur, Fédération de recherche Claude Lalanne, Institut de Physique de Nice, CNRS UMR7010, 17 rue Julien Lauprêtre, 06200 Nice, France
| | - Marie Vidal
- Centre Antoine Lacassagne, Fédération de recherche Claude Lalanne, 227 avenue de la Lanterne, 06200 Nice, France
| | - Joël Hérault
- Centre Antoine Lacassagne, Fédération de recherche Claude Lalanne, 227 avenue de la Lanterne, 06200 Nice, France
| | - Mourad Benabdesselam
- Université Côte d'Azur, Fédération de recherche Claude Lalanne, Institut de Physique de Nice, CNRS UMR7010, 17 rue Julien Lauprêtre, 06200 Nice, France
| | - Petter Hofverberg
- Centre Antoine Lacassagne, Fédération de recherche Claude Lalanne, 227 avenue de la Lanterne, 06200 Nice, France
| | - Franck Mady
- Université Côte d'Azur, Fédération de recherche Claude Lalanne, Institut de Physique de Nice, CNRS UMR7010, 17 rue Julien Lauprêtre, 06200 Nice, France
| |
Collapse
|
3
|
Jacquet M, Ansari S, Gallin-Martel ML, André A, Boursier Y, Dupont M, Es-smimih J, Gallin-Martel L, Hérault J, Hoarau C, Hofverberg JP, Maneval D, Morel C, Muraz JF, Salicis F, Marcatili S. A high sensitivity Cherenkov detector for prompt gamma timing and time imaging. Sci Rep 2023; 13:3609. [PMID: 36869125 PMCID: PMC9984540 DOI: 10.1038/s41598-023-30712-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 02/28/2023] [Indexed: 03/05/2023] Open
Abstract
We recently proposed a new approach for the real-time monitoring of particle therapy treatments with the goal of achieving high sensitivities on the particle range measurement already at limited counting statistics. This method extends the Prompt Gamma (PG) timing technique to obtain the PG vertex distribution from the exclusive measurement of particle Time-Of-Flight (TOF). It was previously shown, through Monte Carlo simulation, that an original data reconstruction algorithm (Prompt Gamma Time Imaging) allows to combine the response of multiple detectors placed around the target. The sensitivity of this technique depends on both the system time resolution and the beam intensity. At reduced intensities (Single Proton Regime-SPR), a millimetric proton range sensitivity can be achieved, provided the overall PG plus proton TOF can be measured with a 235 ps (FWHM) time resolution. At nominal beam intensities, a sensitivity of a few mm can still be obtained by increasing the number of incident protons included in the monitoring procedure. In this work we focus on the experimental feasibility of PGTI in SPR through the development of a multi-channel, Cherenkov-based PG detector with a targeted time resolution of 235 ps (FWHM): the TOF Imaging ARrAy (TIARA). Since PG emission is a rare phenomenon, TIARA design is led by the concomitant optimisation of its detection efficiency and Signal to Noise Ratio (SNR). The PG module that we developed is composed of a small PbF[Formula: see text] crystal coupled to a silicon photoMultiplier to provide the time stamp of the PG. This module is currently read in time coincidence with a diamond-based beam monitor placed upstream the target/patient to measure the proton time of arrival. TIARA will be eventually composed of 30 identical modules uniformly arranged around the target. The absence of a collimation system and the use of Cherenkov radiators are both crucial to increase the detection efficiency and the SNR, respectively. A first prototype of the TIARA block detector was tested with 63 MeV protons delivered from a cyclotron: a time resolution of 276 ps (FWHM) was obtained, resulting in a proton range sensitivity of 4 mm at 2[Formula: see text] with the acquisition of only 600 PGs. A second prototype was also evaluated with 148 MeV protons delivered from a synchro-cyclotron obtaining a time resolution below 167 ps (FWHM) for the gamma detector. Moreover, using two identical PG modules, it was shown that a uniform sensitivity on the PG profiles would be achievable by combining the response of gamma detectors uniformly distributed around the target. This work provides the experimental proof-of-concept for the development of a high sensitivity detector that can be used to monitor particle therapy treatments and potentially act in real-time if the irradiation does not comply to treatment plan.
Collapse
Affiliation(s)
- Maxime Jacquet
- grid.5676.20000000417654326Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - Saba Ansari
- grid.5676.20000000417654326Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - Marie-Laure Gallin-Martel
- grid.5676.20000000417654326Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - Adélie André
- grid.5676.20000000417654326Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - Yannick Boursier
- grid.470046.10000 0004 0452 0652Aix-Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - Mathieu Dupont
- grid.470046.10000 0004 0452 0652Aix-Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - Jilali Es-smimih
- Ion beam application SA, 3, chemin du Cyclotron, 1348 Louvain-La-Neuve, Belgium
| | - Laurent Gallin-Martel
- grid.5676.20000000417654326Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - Joël Hérault
- grid.417812.90000 0004 0639 1794Centre Antoine Lacassagne, 06200 Nice, France
| | - Christophe Hoarau
- grid.5676.20000000417654326Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | | | - Daniel Maneval
- grid.417812.90000 0004 0639 1794Centre Antoine Lacassagne, 06200 Nice, France
| | - Christian Morel
- grid.470046.10000 0004 0452 0652Aix-Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - Jean-François Muraz
- grid.5676.20000000417654326Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - Fabrice Salicis
- Ion beam application SA, 3, chemin du Cyclotron, 1348 Louvain-La-Neuve, Belgium
| | - Sara Marcatili
- Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000, Grenoble, France.
| |
Collapse
|
4
|
Hérault J, Gérard A, Carnicer A, Aloi D, Peyrichon ML, Barnel C, Vidal M, Angellier G, Fayaud D, Grini JC, Giusto A, Armando C, Donadey G, Cabannes M, Dumas S, Payan Y, Di Carlo JF, Salicis C, Bergerot JM, Rolion M, Trimaud R, Hofverberg P, Mandrillon P, Sauerwein W, Thariat J. 30 years of ocular proton therapy, the Nice view. Cancer Radiother 2022; 26:1016-1026. [PMID: 35803860 DOI: 10.1016/j.canrad.2022.03.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 03/15/2022] [Indexed: 11/08/2022]
Abstract
PURPOSE Radiotherapy with protons (PT) is a standard treatment of ocular tumors. It achieves excellent tumor control, limited toxicities, and the preservation of important functional outcomes, such as vision. Although PT may appear as one homogenous technique, it can be performed using dedicated ocular passive scattering PT or, increasingly, Pencil Beam Scanning (PBS), both with various degrees of patient-oriented customization. MATERAIAL AND METHODS MEDICYC PT facility of Nice are detailed with respect to their technical, dosimetric, microdosimetric and radiobiological, patient and tumor-customization process of PT planning and delivery that are key. 6684 patients have been treated for ocular tumors (1991-2020). Machine characteristics (accelerator, beam line, beam monitoring) allow efficient proton extraction, high dose rate, sharp lateral and distal penumbrae, and limited stray radiation in comparison to beam energy reduction and subsequent straggling with high-energy PBS PT. Patient preparation before PT includes customized setup and image-guidance, CT-based planning, and ocular PT software modelling of the patient eye with integration of beam modifiers. Clinical reports have shown excellent tumor control rates (∼95%), vision preservation and limited toxicity rates (papillopathy, retinopathy, neovascular glaucoma, dry eye, madarosis, cataract). RESULTS Although demanding, dedicated ocular PT has proven its efficiency in achieving excellent tumor control, OAR sparing and patient radioprotection. It is therefore worth adaptations of the equipments and practice. CONCLUSIONS Some of these adaptations can be transferred to other PT centers and should be acknowledeged when using non-PT options.
Collapse
Affiliation(s)
- J Hérault
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France.
| | - A Gérard
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - A Carnicer
- IDOM Consulting, Engineering, Architecture, Avinguda de la Fama, 11-15, Arboretum Business Park, Arce Building, 08940 Cornellà de Llobregat, Barcelona, Spain
| | - D Aloi
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - M-L Peyrichon
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - C Barnel
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - M Vidal
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - G Angellier
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - D Fayaud
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - J-C Grini
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - A Giusto
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - C Armando
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - G Donadey
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - M Cabannes
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - S Dumas
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - Y Payan
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - J-F Di Carlo
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - C Salicis
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - J-M Bergerot
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - M Rolion
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - R Trimaud
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - P Hofverberg
- Institut Méditerranéen de ProtonThérapie, Centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - P Mandrillon
- AIMA Development, 227, avenue de la Lanterne, 06200 Nice, France
| | - W Sauerwein
- NCTeam, Strahlenklinik, Universitätsklinikum Essen, Hufelandstraße 55, 45122 Essen, Germany
| | - J Thariat
- Department of Radiation Oncology, Centre François Baclesse, 14000 Caen, France; Laboratoire de Physique Corpusculaire IN2P3/ENSICAEN-UMR6534-Unicaen-Normandie Université, 14000 Caen, France
| |
Collapse
|
5
|
Schauer J, Lascaud J, Huang Y, Vidal M, Hérault J, Dollinger G, Parodi K, Wieser HP. FEASABILITY STUDY OF IONOACOUSTIC SIGNAL DETECTION UNDER FLASH CONDITIONS AT A CLINICAL SYNCHROCYLOTRON FACILITY. Phys Med 2022. [DOI: 10.1016/s1120-1797(22)01696-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
6
|
Wieser HP, Huang Y, Schauer J, Lascaud J, Würl M, Lehrack S, Radonic D, Vidal M, Hérault J, Chmyrov A, Ntziachristos V, Assmann W, Parodi K, Dollinger G. Experimental demonstration of accurate Bragg peak localization with ionoacoustic tandem phase detection (iTPD). Phys Med Biol 2021; 66. [PMID: 34847532 DOI: 10.1088/1361-6560/ac3ead] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Accepted: 11/30/2021] [Indexed: 11/12/2022]
Abstract
Accurate knowledge of the exact stopping location of ions inside the patient would allow full exploitation of their ballistic properties for patient treatment. The localized energy deposition of a pulsed particle beam induces a rapid temperature increase of the irradiated volume and leads to the emission of ionoacoustic (IA) waves. Detecting the time-of-flight (ToF) of the IA wave allows inferring information on the Bragg peak location and can henceforth be used forin-vivorange verification. A challenge for IA is the poor signal-to-noise ratio at clinically relevant doses and viable machines. We present a frequency-based measurement technique, labeled as ionoacoustic tandem phase detection (iTPD) utilizing lock-in amplifiers. The phase shift of the IA signal to a reference signal is measured to derive theToF. Experimental IA measurements with a 3.5 MHz lead zirconate titanate (PZT) transducer and lock-in amplifiers were performed in water using 22 MeV proton bursts. A digital iTPD was performedin-silicoat clinical dose levels on experimental data obtained from a clinical facility and secondly, on simulations emulating a heterogeneous geometry. For the experimental setup using 22 MeV protons, a localization accuracy and precision obtained through iTPD deviates from a time-based reference analysis by less than 15μm. Several methodological aspects were investigated experimentally in systematic manner. Lastly, iTPD was evaluatedin-silicofor clinical beam energies indicating that iTPD is in reach of sub-mm accuracy for fractionated doses < 5 Gy. iTPD can be used to accurately measure theToFof IA signals online via its phase shift in frequency domain. An application of iTPD to the clinical scenario using a single pulsed beam is feasible but requires further development to reach <1 Gy detection capabilities.
Collapse
Affiliation(s)
- H P Wieser
- Department for Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, D-85748 Garching b. München, Germany
| | - Y Huang
- Chair of Biological Imaging (CBI) and Center for Translational Cancer Research (TranslaTUM) Technical University Munich, D-81675 Munich, Germany.,Institute of Biological and Medical Imaging (IBMI), Helmholtz Zentrum München, D-85764 Neuherberg, Germany
| | - J Schauer
- Institute for Applied Physics and Metrology, Department of Aerospace Engineering, Universität der Bundeswehr München, D-85577 Neubiberg, Germany
| | - J Lascaud
- Department for Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, D-85748 Garching b. München, Germany
| | - M Würl
- Department for Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, D-85748 Garching b. München, Germany
| | - S Lehrack
- Department for Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, D-85748 Garching b. München, Germany
| | - D Radonic
- Department for Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, D-85748 Garching b. München, Germany
| | - M Vidal
- Centre Antoine Lacassagne-Fédération Claude Lalanne, 227 avenue de Lanterne, F-06200 Nice, France
| | - J Hérault
- Centre Antoine Lacassagne-Fédération Claude Lalanne, 227 avenue de Lanterne, F-06200 Nice, France
| | - A Chmyrov
- Chair of Biological Imaging (CBI) and Center for Translational Cancer Research (TranslaTUM) Technical University Munich, D-81675 Munich, Germany.,Institute of Biological and Medical Imaging (IBMI), Helmholtz Zentrum München, D-85764 Neuherberg, Germany
| | - V Ntziachristos
- Chair of Biological Imaging (CBI) and Center for Translational Cancer Research (TranslaTUM) Technical University Munich, D-81675 Munich, Germany.,Institute of Biological and Medical Imaging (IBMI), Helmholtz Zentrum München, D-85764 Neuherberg, Germany
| | - W Assmann
- Department for Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, D-85748 Garching b. München, Germany
| | - K Parodi
- Department for Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, D-85748 Garching b. München, Germany
| | - G Dollinger
- Institute for Applied Physics and Metrology, Department of Aerospace Engineering, Universität der Bundeswehr München, D-85577 Neubiberg, Germany
| |
Collapse
|
7
|
Schnürle K, Bortfeldt J, Englbrecht F, Gianoli C, Hartmann J, Hofverberg P, Meyer S, Vidal M, Hérault J, Schreiber J, Parodi K, Würl M. Development of integration mode proton imaging with a single CMOS detector for a small animal irradiation platform. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00094-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Jacquet M, Marcatili S, Gallin-Martel ML, Bouly JL, Boursier Y, Dauvergne D, Dupont M, Gallin-Martel L, Hérault J, Létang JM, Manéval D, Morel C, Muraz JF, Testa É. A time-of-flight-based reconstruction for real-time prompt-gamma imaging in proton therapy. Phys Med Biol 2021; 66. [PMID: 34020438 DOI: 10.1088/1361-6560/ac03ca] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Accepted: 05/21/2021] [Indexed: 11/12/2022]
Abstract
We propose a novel prompt-gamma (PG) imaging modality for real-time monitoring in proton therapy: PG time imaging (PGTI). By measuring the time-of-flight (TOF) between a beam monitor and a PG detector, our goal is to reconstruct the PG vertex distribution in 3D. In this paper, a dedicated, non-iterative reconstruction strategy is proposed (PGTI reconstruction). Here, it was resolved under a 1D approximation to measure a proton range shift along the beam direction. In order to show the potential of PGTI in the transverse plane, a second method, based on the calculation of the centre of gravity (COG) of the TIARA pixel detectors' counts was also explored. The feasibility of PGTI was evaluated in two different scenarios. Under the assumption of a 100 ps (rms) time resolution (achievable in single proton regime), MC simulations showed that a millimetric proton range shift is detectable at 2σwith 108incident protons in simplified simulation settings. With the same proton statistics, a potential 2 mm sensitivity (at 2σwith 108incident protons) to beam displacements in the transverse plane was found using the COG method. This level of precision would allow to act in real-time if the treatment does not conform to the treatment plan. A worst case scenario of a 1 ns (rms) TOF resolution was also considered to demonstrate that a degraded timing information can be compensated by increasing the acquisition statistics: in this case, a 2 mm range shift would be detectable at 2σwith 109incident protons. By showing the feasibility of a time-based algorithm for the reconstruction of the PG vertex distribution for a simplified anatomy, this work poses a theoretical basis for the future development of a PG imaging detector based on the measurement of particle TOF.
Collapse
Affiliation(s)
- Maxime Jacquet
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3 UMR 5821, F-38000 Grenoble, France
| | - Sara Marcatili
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3 UMR 5821, F-38000 Grenoble, France
| | | | - Jean-Luc Bouly
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3 UMR 5821, F-38000 Grenoble, France
| | | | - Denis Dauvergne
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3 UMR 5821, F-38000 Grenoble, France
| | | | - Laurent Gallin-Martel
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3 UMR 5821, F-38000 Grenoble, France
| | | | - Jean-Michel Létang
- University of Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, F-69373 Lyon, France
| | | | | | - Jean-François Muraz
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3 UMR 5821, F-38000 Grenoble, France
| | - Étienne Testa
- Univ. Lyon, Univ. Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, F-69622, Villeurbanne, France
| |
Collapse
|
9
|
Gerlach S, Pinto M, Kurichiyanil N, Grau C, Hérault J, Hillbrand M, Poulsen PR, Safai S, Schippers JM, Schwarz M, Søndergaard CS, Tommasino F, Verroi E, Vidal M, Yohannes I, Schreiber J, Parodi K. Corrigendum: Beam characterization and feasibility study for a small animal irradiation platform at clinical proton therapy facilities (2020 Phys. Med. Biol.65 245045). Phys Med Biol 2021; 66. [PMID: 34037545 DOI: 10.1088/1361-6560/abf00e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 03/18/2021] [Indexed: 11/11/2022]
Affiliation(s)
- S Gerlach
- Department for Medical Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - M Pinto
- Department for Medical Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - N Kurichiyanil
- Department for Medical Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - C Grau
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.,Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - J Hérault
- Centre Antoine Lacassagne, Nice, France.,Fédération Claude Lalanne-Université Côte d'Azur, Nice, France
| | - M Hillbrand
- Rinecker Proton Therapy Center, München, Germany
| | - P R Poulsen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.,Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - S Safai
- Paul Scherrer Institute, Villigen, Switzerland
| | | | - M Schwarz
- Trento Institute for Fundamental Physics and Applications, National Institute for Nuclear Physics, Povo, Italy.,Protontherapy Department, Azienda Provinciale per i Servizi Sanitari, Trento, Italy
| | - C S Søndergaard
- Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - F Tommasino
- Trento Institute for Fundamental Physics and Applications, National Institute for Nuclear Physics, Povo, Italy.,Department of Physics, University of Trento, Povo, Italy
| | - E Verroi
- Trento Institute for Fundamental Physics and Applications, National Institute for Nuclear Physics, Povo, Italy
| | - M Vidal
- Centre Antoine Lacassagne, Nice, France.,Fédération Claude Lalanne-Université Côte d'Azur, Nice, France
| | - I Yohannes
- Rinecker Proton Therapy Center, München, Germany
| | - J Schreiber
- Department for Medical Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - K Parodi
- Department for Medical Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| |
Collapse
|
10
|
Gerlach S, Pinto M, Kurichiyanil N, Grau C, Hérault J, Hillbrand M, Poulsen PR, Safai S, Schippers JM, Schwarz M, Søndergaard CS, Tommasino F, Verroi E, Vidal M, Yohannes I, Schreiber J, Parodi K. Beam characterization and feasibility study for a small animal irradiation platform at clinical proton therapy facilities. Phys Med Biol 2020; 65:245045. [DOI: 10.1088/1361-6560/abc832] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
11
|
Colnard-Hofverberg C, Gautier M, Dejean C, Feuillade J, Burgaud L, Mana A, Lhomel B, Hérault J. 65 Dosimetric measurements with Gafchromic EBT-3 films for the new 50kV Papillon+ intraoperative therapy system. Phys Med 2019. [DOI: 10.1016/j.ejmp.2019.09.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
12
|
Carnicer A, Candela-Juan C, Nirrengarten M, Blideanu V, Mazal A, Hérault J, Delacroix S. Activation of Collimators Irradiated With Clinical Proton Beams and Development of a Semiempirical Model for Activity Calculation. Health Phys 2019; 117:509-525. [PMID: 31211755 DOI: 10.1097/hp.0000000000001082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Patient-specific collimators used in proton therapy are activated after use. The aim of this work is to assess the residual activity in brass collimators considering clinical beams, so far studied only for monoenergetic beams, and to develop a model to calculate the activity. Eight brass collimators irradiated with different clinical and monoenergetic beams were included in the study. The collimators were analyzed with gamma spectrometry in the framework of three independent studies carried out at the two French proton therapy sites. Using FLUKA (a fully integrated particle physics Monte Carlo simulation package), simulations were performed to determine radionuclides and activities for all the collimators. The semiempirical model was built using data calculated with FLUKA for a range of clinical beams (different maximum proton energies, modulations, and doses). It was found that there was global coherence in experimental results from different studies. The relevant radionuclides at 1 mo postirradiation were Co, Co, and Zn, and additionally, Mn, Co, and Co for high-energy beams. For nondegraded monoenergetic beams, differences between FLUKA and spectrometry were within those reported in reference benchmark studies (±30%). Due to the use of perfect monochromatic sources in the FLUKA model, FLUKA results systematically underestimated experimental activities for clinical beams, especially for Zn, depending on the beam energy spread (modulation, degradation, beam line characteristics). To account for the energy spread, correction factors were derived for the semiempirical model. The model is applicable to the most relevant radionuclides and total amounts. Secondary neutrons have a negligible contribution to the activity during treatment with respect to proton activation.
Collapse
Affiliation(s)
| | | | | | - Valentin Blideanu
- Commissariat à l'énergie atomique (CEA-Saclay), Gif-sur-Yvette, France
| | - Alejandro Mazal
- Centre de Protonthérapie d'Orsay Institut Curie (ICPO), Orsay, France
| | | | - Sabine Delacroix
- Centre de Protonthérapie d'Orsay Institut Curie (ICPO), Orsay, France
| |
Collapse
|
13
|
Beddok A, Vela A, Calugaru V, Tessonnier T, Kubes J, Dutheil P, Gérard A, Vidal M, Goudjil F, Florescu C, Kammerer E, Bénézery K, Hérault J, Bourhis J, Thariat J. Protonthérapie des carcinomes épidermoïdes des voies aérodigestives supérieures : de la physique à la clinique. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Beddok A, Vela A, Calugaru V, Tessonnier T, Kubes J, Dutheil P, Gérard A, Idal M, Goudjil F, Florescu C, Kammerer E, Bénézery K, Hérault J, Bourhis J, Thariat J. Protonthérapie des carcinomes épidermoïdes des voies aérodigestives supérieures : de la physique à la clinique. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Beddok A, Vela A, Calugaru V, Tessonnier T, Kubes J, Dutheil P, Gérard A, Vidal M, Goudjil F, Florescu C, Kammerer E, Bénézery K, Hérault J, Bourhis J, Thariat J. [Proton therapy for head and neck squamous cell carcinomas: From physics to clinic]. Cancer Radiother 2019; 23:439-448. [PMID: 31358445 DOI: 10.1016/j.canrad.2019.05.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 05/09/2019] [Accepted: 05/16/2019] [Indexed: 11/17/2022]
Abstract
Intensity-modulated radiation therapy (IMRT) is presently the recommended technique for the treatment of locally advanced head and neck carcinomas. Proton therapy would allow to reduce the volume of irradiated normal tissue and, thus, to decrease the risk of late dysphagia, xerostomia, dysgeusia and hypothyroidism. An exhaustive research was performed with the search engine PubMed by focusing on the papers about the physical difficulties that slow down use of proton therapy for head and neck carcinomas. Range uncertainties in proton therapy (±3 %) paradoxically limit the use of the steep dose gradient in distality. Calibration uncertainties can be important in the treatment of head and neck cancer in the presence of materials of uncertain stoichiometric composition (such as with metal implants, dental filling, etc.) and complex heterogeneities. Dental management for example may be different with IMRT or proton therapy. Some uncertainties can be somewhat minimized at the time of optimization. Inter- and intrafractional variations and uncertainties in Hounsfield units/stopping power can be integrated in a robust optimization process. Additional changes in patient's anatomy (tumour shrinkage, changes in skin folds in the beam patch, large weight loss or gain) require rescanning. Dosimetric and small clinical studies comparing photon and proton therapy have well shown the interest of proton therapy for head and neck cancers. Intensity-modulated proton therapy is a promising treatment as it can reduce the substantial toxicity burden of patients with head and neck squamous cell carcinoma compared to IMRT. Robust optimization will allow to perform an optimal treatment and to use proton therapy in current clinical practice.
Collapse
Affiliation(s)
- A Beddok
- Département d'oncologie-radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France
| | - A Vela
- Département d'oncologie-radiothérapie, centre François-Baclesse, Caen, 3, avenue du Général-Harris, 14000 Caen, France; Unicaen - Normandie Université, 14000 Caen, France; Advanced Resource Centre for Hadrontherapy in Europe (Archade), 3, avenue du Général-Harris, 14000 Caen, France
| | - V Calugaru
- Département d'oncologie-radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France
| | - T Tessonnier
- Département d'oncologie-radiothérapie, centre François-Baclesse, Caen, 3, avenue du Général-Harris, 14000 Caen, France; Unicaen - Normandie Université, 14000 Caen, France; Advanced Resource Centre for Hadrontherapy in Europe (Archade), 3, avenue du Général-Harris, 14000 Caen, France
| | - J Kubes
- Proton Therapy Centre Czech, Prague, République tchèque
| | - P Dutheil
- Département d'oncologie-radiothérapie, centre François-Baclesse, Caen, 3, avenue du Général-Harris, 14000 Caen, France; Unicaen - Normandie Université, 14000 Caen, France; Advanced Resource Centre for Hadrontherapy in Europe (Archade), 3, avenue du Général-Harris, 14000 Caen, France
| | - A Gérard
- Centre Antoine-Lacassagne, département d'oncologie-radiothérapie, 33, avenue Valombrose, 06000 Nice, France
| | - M Vidal
- Centre Antoine-Lacassagne, département d'oncologie-radiothérapie, 33, avenue Valombrose, 06000 Nice, France
| | - F Goudjil
- Département d'oncologie-radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France
| | - C Florescu
- Département d'oncologie-radiothérapie, centre François-Baclesse, Caen, 3, avenue du Général-Harris, 14000 Caen, France; Unicaen - Normandie Université, 14000 Caen, France; Advanced Resource Centre for Hadrontherapy in Europe (Archade), 3, avenue du Général-Harris, 14000 Caen, France
| | - E Kammerer
- Département d'oncologie-radiothérapie, centre François-Baclesse, Caen, 3, avenue du Général-Harris, 14000 Caen, France; Unicaen - Normandie Université, 14000 Caen, France; Advanced Resource Centre for Hadrontherapy in Europe (Archade), 3, avenue du Général-Harris, 14000 Caen, France
| | - K Bénézery
- Centre Antoine-Lacassagne, département d'oncologie-radiothérapie, 33, avenue Valombrose, 06000 Nice, France
| | - J Hérault
- Centre Antoine-Lacassagne, département d'oncologie-radiothérapie, 33, avenue Valombrose, 06000 Nice, France
| | - J Bourhis
- Département d'oncologie-radiothérapie, centre hospitalier universitaire vaudois, Lausanne, Suisse
| | - J Thariat
- Département d'oncologie-radiothérapie, centre François-Baclesse, Caen, 3, avenue du Général-Harris, 14000 Caen, France; Unicaen - Normandie Université, 14000 Caen, France; Advanced Resource Centre for Hadrontherapy in Europe (Archade), 3, avenue du Général-Harris, 14000 Caen, France; Laboratoire de physique corpusculaire IN2P3/Ensicaen - UMR6534, Unicaen - Normandie Université, 14000 Caen, France.
| | -
- Département d'oncologie-radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France; Département d'oncologie-radiothérapie, centre François-Baclesse, Caen, 3, avenue du Général-Harris, 14000 Caen, France; Unicaen - Normandie Université, 14000 Caen, France; Proton Therapy Centre Czech, Prague, République tchèque; Centre Antoine-Lacassagne, département d'oncologie-radiothérapie, 33, avenue Valombrose, 06000 Nice, France; Département d'oncologie-radiothérapie, centre hospitalier universitaire vaudois, Lausanne, Suisse; Laboratoire de physique corpusculaire IN2P3/Ensicaen - UMR6534, Unicaen - Normandie Université, 14000 Caen, France
| |
Collapse
|
16
|
Peucelle C, Gérard A, Maneval D, Vidal M, Falk A, Hérault J. PO-0910 Lumbosacral proton therapy treatment of a patient with large spine metal implants. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31330-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Carnicer A, Angellier G, Hofverberg P, Bergerot JM, Gerard A, Peucelle C, Vidal M, Hérault J. Study of the responses and calibration procedures of neutron and gamma area and environmental detectors for use in proton therapy. J Radiol Prot 2019; 39:250-278. [PMID: 30721148 DOI: 10.1088/1361-6498/aaf437] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Ambient dose equivalent measurements with radiation protection instruments are associated to large uncertainties, mostly due to the energy dependence of the instrument response and to the dissimilarity between the spectra of the standard calibration source and the workplace field. The purpose of this work is to evaluate its impact on the performance of area and environmental detectors in the proton therapy environment, and to provide practical solutions whenever needed and possible. The study was carried out at the Centre Antoine Lacassagne (CAL) proton therapy site, and included a number of commercially available area detectors and a home-made environmental thermoluminescent dosimeter based on a polyethylene moderator loaded with TLD600H/TLD700H pairs. Monte Carlo simulations were performed with MCNP to calculate, first, missing or partially lacking instrument responses, covering the range of energies involved in proton therapy. Second, neutron and gamma spectra were computed at selected positions in and outside the CAL proton therapy bunkers. Appropriate correction factors were then derived for each detector, workplace location and calibration radionuclide source, which amounts to up to 1.9 and 1.5 for neutron and photon area detectors, respectively, and suggest that common ambient dose equivalent instruments might not meet IEC requirements. The TLD environmental system was calibrated in situ and appropriate correction factors were applied to account for the cosmic spectra. Measurements performed with this system from 2014 to 2017 around the installation were consistent with reference natural background dose data and with pre-operational levels registered at the site before the construction of the building in 1988, showing thus no contribution from the site clinical activities. An in situ verification procedure for the radiation protection instruments was also implemented in 2016 at the low energy treatment room using the QA beam reference conditions. The method presents main methodological, practical and economic advantages over external verifications.
Collapse
Affiliation(s)
- Adela Carnicer
- Centre Antoine Lacassagne (CAL), 227 avenue de la Lanterne, 06200 Nice, France. Fédération Claude Lalanne-Université Côte d'Azur, France
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Duboz JY, Zucchi J, Frayssinet E, Chalbet P, Chenot S, Hugues M, Grini JC, Trimaud R, Vidal M, Hérault J. GaN Schottky diodes for proton beam monitoring. Biomed Phys Eng Express 2019. [DOI: 10.1088/2057-1976/aaf9b4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
19
|
Mathis T, Hofverberg P, Caujolle JP, Hérault J, Leal C, Maschi C, Delaunay B, Baillif S, Kodjikian L, Thariat J. Occurrence of Phosphenes in Patients Undergoing Proton Beam Therapy for Ocular Tumor. Am J Ophthalmol 2018; 192:31-38. [PMID: 29753854 DOI: 10.1016/j.ajo.2018.05.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 04/06/2018] [Accepted: 05/02/2018] [Indexed: 11/19/2022]
Abstract
PURPOSE Phosphenes are frequently reported by patients irradiated in the head and neck area. The aim of the present study was to characterize and investigate potential mechanisms of proton beam therapy (PBT)-induced phosphenes in a large population of patients undergoing PBT for ocular tumors. DESIGN Prospective cohort study. METHODS Consecutive patients who underwent PBT in a single center were included. Immediately after the first session, all patients completed a questionnaire collecting information about the presence of phosphenes as well as their color, shape, and duration. Patient, tumor and treatment characteristics (dose volume histograms) were also collected. RESULTS Among the 474 patients included, 62.8% reported phosphenes during the first session of PBT. Reported colors were mainly blue-violet (70.5%) and white (14.1%). The prevalence of phosphenes was higher in younger patients (P = .003); other patient or ocular characteristics were not associated with the occurrence of phosphenes. Irradiation of the macula (P < .001) and/or optic disc (P < .001) were significantly associated with the presence of phosphenes, whereas blue-violet color was only associated with young age and irradiation of macular area (P = .04). Pupillary constriction was reported for 57.1% of patients with phosphenes vs 18.5% of patients without (P < .001). Blue-violet phosphenes (P < .001) and irradiation of macula (P = .001) were statistically associated with pupillary constriction. CONCLUSIONS The present study reported a high rate of phosphenes in patients irradiated by PBT for ocular tumor. Their blue-violet color and their association with a pupillary constriction probably indicates the stimulation of S-cones and retinal ganglion cells that reflects the activation of the afferent visual pathway.
Collapse
Affiliation(s)
- Thibaud Mathis
- Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France; UMR-CNRS 5510 Matéis, Villeurbane, France.
| | - Petter Hofverberg
- Department of Radiation Therapy, Proton Therapy Center, Centre Antoine Lacassagne, Nice, France
| | | | - Joël Hérault
- Department of Radiation Therapy, Proton Therapy Center, Centre Antoine Lacassagne, Nice, France
| | - Cécilia Leal
- Department of Ophthalmology, Pasteur II Hospital, Nice, France
| | - Celia Maschi
- Department of Ophthalmology, Pasteur II Hospital, Nice, France
| | - Benoit Delaunay
- Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France
| | | | - Laurent Kodjikian
- Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France; UMR-CNRS 5510 Matéis, Villeurbane, France
| | - Juliette Thariat
- Department of Radiation Therapy, Centre François Baclesse - ARCHADE, Unicaen - Normandie University, Caen, France
| |
Collapse
|
20
|
Wanko N, Vidal M, Gérard A, Hérault J. 32. To Proton therapy quality assurance optimization through a new phantom design. Phys Med 2017. [DOI: 10.1016/j.ejmp.2017.10.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
21
|
Westekemper H, Meller D, Darawsha R, Scholz SL, Flühs D, Steuhl KP, Hérault J, Thariat J, Sauerwein W. [Operative therapy and irradiation of conjunctival melanoma]. Ophthalmologe 2016; 112:899-900, 902-6. [PMID: 26475337 DOI: 10.1007/s00347-015-0147-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND Radiotherapy of conjunctival melanoma has gained in importance in recent years compared to less invasive therapeutic approaches. This is due to the high recurrence rates achieved by omitting adjuvant therapy and to the increasing availability of suitable radiotherapeutic methods, so that tumors formerly not amenable to organ-preserving therapy can now be treated. OBJECTIVE This article presents the current radiotherapeutic options for conjunctival melanoma. The aim is to describe the diagnostic and therapeutic strategies and the course of therapy of malignant conjunctival melanoma. It is the authors' intention to justify the necessity of the adjuvant therapy of conjunctival melanoma and to emphasize the need for interdisciplinary cooperation during the course of tumor therapy. METHODS The article is based on results published in the literature as well as on data collected and experience gained in our centre.
Collapse
Affiliation(s)
- H Westekemper
- Klinik für Erkrankungen des vorderen Augenabschnitts, Zentrum für Augenheilkunde, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland.
| | - D Meller
- Klinik für Erkrankungen des vorderen Augenabschnitts, Zentrum für Augenheilkunde, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland
| | - R Darawsha
- Klinik für Erkrankungen des vorderen Augenabschnitts, Zentrum für Augenheilkunde, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland
| | - S L Scholz
- Klinik für Erkrankungen des vorderen Augenabschnitts, Zentrum für Augenheilkunde, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland
| | - D Flühs
- Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Deutschland
| | - K-P Steuhl
- Klinik für Erkrankungen des vorderen Augenabschnitts, Zentrum für Augenheilkunde, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland
| | - J Hérault
- Cyclotron Biomédical, Centre Antoine-Lacassagne, Nice, France
| | - J Thariat
- Cyclotron Biomédical, Centre Antoine-Lacassagne, Nice, France
| | - W Sauerwein
- Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Deutschland
| |
Collapse
|
22
|
Doyen J, Bondiau PY, Benezery K, Thariat J, Vidal M, Gérard A, Hérault J, Carrie C, Hannoun-Lévi JM. [Indications and results for protontherapy in cancer treatments]. Cancer Radiother 2016; 20:513-8. [PMID: 27614508 DOI: 10.1016/j.canrad.2016.06.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2016] [Accepted: 06/10/2016] [Indexed: 12/16/2022]
Abstract
Purpose was to summarize results for proton therapy in cancer treatment. A systematic review has been done by selecting studies on the website www.pubmed.com (Medline) and using the following keywords: proton therapy, radiation therapy, cancer, chordoma, chondrosarcoma, uveal melanoma, retinoblastoma, meningioma, glioma, neurinoma, pituitary adenoma, medulloblastoma, ependymoma, craniopharyngioma and nasal cavity. There are several retrospective studies reporting results for proton therapy in cancer treatments in the following indications: ocular tumors, nasal tumors, skull-based tumors, pediatric tumors. There is no prospective study except one phase II trial in medulloblastoma. The use of proton therapy for these indications is due to dosimetric advantages offering better tumor coverage and organ at risk sparing in comparison with photon therapy. Clinical results are historically at least as efficient as photon therapy with a better toxicity profile in pediatric tumors (cognitive and endocrine functions, radiation-induced cancer) and a better tumoral control in tumors of the nasal cavity. Clinical advantages of proton therapy counterbalance its cost especially in pediatric tumors. Proton therapy could be used in other types of cancer. Proton therapy showed good outcome in ocular, nasal tumors, pediatric, skull-based and paraspinal tumors. Because of some dosimetric advantages, proton therapy could be proposed for other indications in cancer treatments.
Collapse
Affiliation(s)
- J Doyen
- Centre Antoine-Lacassagne, radiation oncology, 33, avenue de Valombrose, 06189 Nice, France.
| | - P-Y Bondiau
- Centre Antoine-Lacassagne, radiation oncology, 33, avenue de Valombrose, 06189 Nice, France
| | - K Benezery
- Centre Antoine-Lacassagne, radiation oncology, 33, avenue de Valombrose, 06189 Nice, France
| | - J Thariat
- Centre Antoine-Lacassagne, radiation oncology, 33, avenue de Valombrose, 06189 Nice, France
| | - M Vidal
- Centre Antoine-Lacassagne, radiation oncology, 33, avenue de Valombrose, 06189 Nice, France
| | - A Gérard
- Centre Antoine-Lacassagne, radiation oncology, 33, avenue de Valombrose, 06189 Nice, France
| | - J Hérault
- Centre Antoine-Lacassagne, radiation oncology, 33, avenue de Valombrose, 06189 Nice, France
| | - C Carrie
- Centre Léon-Bérard, radiation oncology, 28, rue Laennec, 69008 Lyon, France
| | - J-M Hannoun-Lévi
- Centre Antoine-Lacassagne, radiation oncology, 33, avenue de Valombrose, 06189 Nice, France
| |
Collapse
|
23
|
Bensoussan E, Thariat J, Maschi C, Delas J, Schouver ED, Hérault J, Baillif S, Caujolle JP. Outcomes After Proton Beam Therapy for Large Choroidal Melanomas in 492 Patients. Am J Ophthalmol 2016; 165:78-87. [PMID: 26940166 DOI: 10.1016/j.ajo.2016.02.027] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 02/21/2016] [Accepted: 02/21/2016] [Indexed: 11/29/2022]
Abstract
PURPOSE To evaluate proton beam therapy (PBT) as a means to preserve the eye and spare some vision while not deteriorating survival in patients with large choroidal melanomas. DESIGN This is a retrospective, consecutive cohort study of patients with T3-4 choroidal melanomas according to the 7th edition of the American Joint Cancer Classification treated with PBT over a 24-year period. RESULTS A total of 492 patients were included. Mean (range) tumor thickness and diameter were 8.77 (2-15) mm and 14.91 (7-24.1) mm, respectively. Mean macular and optic disc distance were 4.56 (0-19.9) mm and 4.59 (0-22.1) mm, respectively. Mean follow-up was 61.9 months. Rates of neovascular glaucoma (NVG) and enucleation (mainly for local recurrence or NVG) were 27.0% and 19.5%, respectively. Enucleation rates decreased over time. The 5-year local control was 94%. Mean baseline visual acuity was 20/63, and visual acuity ≥20/200 was preserved in 20% of patients. At 5 years, 25% of T3 patients presented with metastasis; overall and specific survival rates were 65% and 75%, respectively. CONCLUSION Local control after PBT remained good with increasingly manageable complications and fewer secondary enucleations over time for these large melanomas. As PBT does not seem to deteriorate survival in these patients having a high risk of metastasis, PBT may be considered as a safe and efficient alternative to enucleation in patients with large choroidal melanoma, and may help to spare some vision.
Collapse
Affiliation(s)
- Elsa Bensoussan
- Department of Ophthalmology, Pasteur Hospital, Nice Teaching Hospital, Nice, France
| | - Juliette Thariat
- Department of Radiation Oncology, Protontherapy Center, Centre Antoine Lacassagne, Nice, France
| | - Célia Maschi
- Department of Ophthalmology, Pasteur Hospital, Nice Teaching Hospital, Nice, France
| | - Jérôme Delas
- Department of Ophthalmology, Pasteur Hospital, Nice Teaching Hospital, Nice, France
| | - Elie Dan Schouver
- Department of Cardiology, Pasteur Hospital, Nice Teaching Hospital, Nice, France
| | - Joël Hérault
- Department of Radiation Oncology, Protontherapy Center, Centre Antoine Lacassagne, Nice, France
| | - Stéphanie Baillif
- Department of Ophthalmology, Pasteur Hospital, Nice Teaching Hospital, Nice, France
| | - Jean-Pierre Caujolle
- Department of Ophthalmology, Pasteur Hospital, Nice Teaching Hospital, Nice, France.
| |
Collapse
|
24
|
Bonfrate A, Farah J, De Marzi L, Delacroix S, Hérault J, Sayah R, Lee C, Bolch WE, Clairand I. Influence of beam incidence and irradiation parameters on stray neutron doses to healthy organs of pediatric patients treated for an intracranial tumor with passive scattering proton therapy. Phys Med 2016; 32:590-9. [PMID: 27050170 DOI: 10.1016/j.ejmp.2016.03.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Revised: 02/05/2016] [Accepted: 03/14/2016] [Indexed: 11/28/2022] Open
Abstract
PURPOSE In scattering proton therapy, the beam incidence, i.e. the patient's orientation with respect to the beam axis, can significantly influence stray neutron doses although it is almost not documented in the literature. METHODS MCNPX calculations were carried out to estimate stray neutron doses to 25 healthy organs of a 10-year-old female phantom treated for an intracranial tumor. Two beam incidences were considered in this article, namely a superior (SUP) field and a right lateral (RLAT) field. For both fields, a parametric study was performed varying proton beam energy, modulation width, collimator aperture and thickness, compensator thickness and air gap size. RESULTS Using a standard beam line configuration for a craniopharyngioma treatment, neutron absorbed doses per therapeutic dose of 63μGyGy(-1) and 149μGyGy(-1) were found at the heart for the SUP and the RLAT fields, respectively. This dose discrepancy was explained by the different patient's orientations leading to changes in the distance between organs and the final collimator where external neutrons are mainly produced. Moreover, investigations on neutron spectral fluence at the heart showed that the number of neutrons was 2.5times higher for the RLAT field compared against the SUP field. Finally, the influence of some irradiation parameters on neutron doses was found to be different according to the beam incidence. CONCLUSION Beam incidence was thus found to induce large variations in stray neutron doses, proving that this parameter could be optimized to enhance the radiation protection of the patient.
Collapse
Affiliation(s)
- A Bonfrate
- IRSN - Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie Externe BP17, 92262 Fontenay-aux-Roses Cedex, France.
| | - J Farah
- IRSN - Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie Externe BP17, 92262 Fontenay-aux-Roses Cedex, France.
| | - L De Marzi
- Institut Curie - Centre de Protonthérapie d'Orsay (CPO) - Campus universitaire bâtiment 101, 91898 Orsay, France
| | - S Delacroix
- Institut Curie - Centre de Protonthérapie d'Orsay (CPO) - Campus universitaire bâtiment 101, 91898 Orsay, France
| | - J Hérault
- Centre Antoine Lacassagne (CAL) - Cyclotron biomédical, 227 avenue de la Lanterne, 06200 Nice, France
| | - R Sayah
- IRSN - Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie Externe BP17, 92262 Fontenay-aux-Roses Cedex, France
| | - C Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Rockville, MD 20850, USA
| | - W E Bolch
- J Crayton Pruitt Family Departments of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA
| | - I Clairand
- IRSN - Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie Externe BP17, 92262 Fontenay-aux-Roses Cedex, France
| |
Collapse
|
25
|
Doyen J, Falk AT, Floquet V, Hérault J, Hannoun-Lévi JM. Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treat Rev 2016; 43:104-12. [PMID: 26827698 DOI: 10.1016/j.ctrv.2015.12.007] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2015] [Revised: 12/24/2015] [Accepted: 12/29/2015] [Indexed: 12/25/2022]
Abstract
PURPOSE To review current evidence of the role of proton therapy (PT) in other tumors than skull base, sinusal/parasinusal, spinal and pediatric tumors; to determine medico-economic aspects raised by PT. MATERIAL AND METHODS A systematic review on Medline was performed with the following keywords: proton therapy, proton beam, protontherapy, cancer; publications with comparison between PT and photon-therapy were also selected. RESULTS In silico studies have shown superiority (better dose delivery to the target and/or to organs at risk) of PT toward photon-therapy in most of thoracic and abdominal malignant tumors. Potential benefits of PT could be: reduction of toxicities (including radiation-induced cancer), increase of tumor control through a dose-escalation approach, hypofractionation. Cost of treatment is always cited as an issue which actually can be managed by a precise patient selection making PT a cost-effective procedure. Comparison plan with photon therapy may be useful to determine the dosimetric and clinical advantages of PT (Normal Tissue Complications Probability). CONCLUSION PT may be associated with a great advantage compared to the best photon-therapies in various types of cancers. Accumulation of clinical data is on-going and will challenge the in silico data analysis. Some indications are associated with strong superiority of PT and may be discussed as a new standard within prospective observational studies.
Collapse
Affiliation(s)
- Jérôme Doyen
- Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Nice-Sophia, Nice, France
| | - Alexander Tuan Falk
- Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Nice-Sophia, Nice, France
| | - Vincent Floquet
- Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Nice-Sophia, Nice, France
| | - Joël Hérault
- Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Nice-Sophia, Nice, France
| | - Jean-Michel Hannoun-Lévi
- Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Nice-Sophia, Nice, France.
| |
Collapse
|
26
|
Claren A, Lupu-Plesu M, Jérôme D, Feuillade J, Hérault J, Pagès G. Modulation de la réponse angiogénique/lymphangiogénique dans le temps en fonction de l’irradiation par protons ou photons. Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.07.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Amblard R, Floquet V, Angellier G, Hannoun-Lévi JM, Hérault J. Imagerie protonique pour la protonthérapie : état de l’art. Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
|
29
|
Amblard R, Floquet V, Angellier G, Hannoun-Lévi JM, Hérault J. [Proton imaging applications for proton therapy: state of the art]. Cancer Radiother 2015; 19:139-51; quiz 152-6. [PMID: 25640216 DOI: 10.1016/j.canrad.2014.04.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Revised: 04/16/2014] [Accepted: 04/30/2014] [Indexed: 11/16/2022]
Abstract
Proton therapy allows a highly precise tumour volume irradiation with a low dose delivered to the healthy tissues. The steep dose gradients observed and the high treatment conformity require a precise knowledge of the proton range in matter and the target volume position relative to the beam. Thus, proton imaging allows an improvement of the treatment accuracy, and thereby, in treatment quality. Initially suggested in 1963, radiographic imaging with proton is still not used in clinical routine. The principal difficulty is the lack of spatial resolution, induced by the multiple Coulomb scattering of protons with nuclei. Moreover, its realization for all clinical locations requires relatively high energies that are previously not considered for clinical routine. Abandoned for some time in favor of X-ray technologies, research into new imaging methods using protons is back in the news because of the increase of proton radiation therapy centers in the world. This article exhibits a non-exhaustive state of the art in proton imaging.
Collapse
Affiliation(s)
- R Amblard
- Cyclotron biomédical, centre Antoine-Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France.
| | - V Floquet
- Cyclotron biomédical, centre Antoine-Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - G Angellier
- Cyclotron biomédical, centre Antoine-Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - J M Hannoun-Lévi
- Cyclotron biomédical, centre Antoine-Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| | - J Hérault
- Cyclotron biomédical, centre Antoine-Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France
| |
Collapse
|
30
|
Carnicer A, Letellier V, Rucka G, Angellier G, Sauerwein W, Hérault J. An indirect in vivo dosimetry system for ocular proton therapy. Radiat Prot Dosimetry 2014; 161:373-376. [PMID: 24222711 DOI: 10.1093/rpd/nct284] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Secondary radiation, particularly neutron radiation, is a cause of concern in proton therapy. However, one can take advantage of its presence by using it to retrieve useful information on the primary proton beam. At the Centre Antoine Lacassagne the secondary radiation in the treatment room has been studied in function of the beam modulation. A strong correlation was found between the secondary ambient dose equivalent per proton dose H*(10)/D and proton dose rate D/MU. A large volume ionisation chamber fixed on the wall at 2.5 m from the nozzle was used with an in-house computer interface to retrieve the value of D/MU derived from the measurement of photon H*(10) integrated over treatment time, using the correlation curve. This system enables the verification of D and D/MU to be made independently of the monitoring of the primary beam and represents a first step towards an alternative in vivo dosimetry in proton therapy.
Collapse
Affiliation(s)
- A Carnicer
- Cyclotron Biomédical, Centre Antoine Lacassagne, 227 Avenue de la Lanterne, 06200 Nice, France
| | - V Letellier
- Centre de protonthérapie, Institut Curie, Campus Universitaire d'Orsay, bâtiment 101, 91898 Orsay Cedex, France
| | - G Rucka
- Centre de radiothérapie St Louis, Hôpital de la Croix Rouge, rue André Blondel, 83100 Toulon France
| | - G Angellier
- Cyclotron Biomédical, Centre Antoine Lacassagne, 227 Avenue de la Lanterne, 06200 Nice, France
| | - W Sauerwein
- Universitätsklinikum Essen, Strahlenklink, 45122 Essen, Germany
| | - J Hérault
- Cyclotron Biomédical, Centre Antoine Lacassagne, 227 Avenue de la Lanterne, 06200 Nice, France
| |
Collapse
|
31
|
Farah J, Sayah R, Martinetti F, Donadille L, Lacoste V, Hérault J, Delacroix S, Nauraye C, Vabre I, Lee C, Bolch WE, Clairand I. Secondary neutron doses in proton therapy treatments of ocular melanoma and craniopharyngioma. Radiat Prot Dosimetry 2014; 161:363-367. [PMID: 24222710 DOI: 10.1093/rpd/nct283] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Monte Carlo simulations were used to assess secondary neutron doses received by patients treated with proton therapy for ocular melanoma and craniopharyngioma. MCNPX calculations of out-of-field doses were done for ∼20 different organs considering realistic treatment plans and using computational phantoms representative of an adult male individual. Simulations showed higher secondary neutron doses for intracranial treatments, ∼14 mGy to the salivary glands, when compared with ocular treatments, ∼0.6 mGy to the non-treated eye. This secondary dose increase is mainly due to the higher proton beam energy (178 vs. 75 MeV) as well as to the impact of the different beam parameters (modulation, collimation, field size etc.). Moreover, when compared with published data, the assessed secondary neutron doses showed similar trends, but sometimes with sensitive differences. This confirms secondary neutrons to be directly dependent on beam energy, modulation technique, treatment configuration and methodology.
Collapse
Affiliation(s)
- J Farah
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France
| | - R Sayah
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France
| | - F Martinetti
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France
| | - L Donadille
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France
| | - V Lacoste
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France
| | - J Hérault
- Centre Antoine Lacassagne (CAL) - Cyclotron biomédical, 227 avenue de la Lanterne, 06200 Nice, France
| | - S Delacroix
- Institut Curie - Centre de Protonthérapie d'Orsay (ICPO) - Campus universitaire bâtiment 101, 91898 Orsay, France
| | - C Nauraye
- Institut Curie - Centre de Protonthérapie d'Orsay (ICPO) - Campus universitaire bâtiment 101, 91898 Orsay, France
| | - I Vabre
- Institut de physique nucléaire (IPN), 91406 Orsay Cedex, France
| | - C Lee
- Division of Cancer Epidemiology and Genetics, National Institute of Health, Bethesda, MD 20852, USA
| | - W E Bolch
- Departments of Nuclear & Radiological and Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA
| | - I Clairand
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France
| |
Collapse
|
32
|
Sayah R, Farah J, Donadille L, Hérault J, Delacroix S, De Marzi L, De Oliveira A, Vabre I, Stichelbaut F, Lee C, Bolch WE, Clairand I. Secondary neutron doses received by paediatric patients during intracranial proton therapy treatments. J Radiol Prot 2014; 34:279-96. [PMID: 24704989 DOI: 10.1088/0952-4746/34/2/279] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
This paper's goal is to assess secondary neutron doses received by paediatric patients treated for intracranial tumours using a 178 MeV proton beam. The MCNPX Monte Carlo model of the proton therapy facility, previously validated through experimental measurements for both proton and neutron dosimetry, was used. First, absorbed dose was calculated for organs located outside the clinical target volume using a series of hybrid computational phantoms for different ages and considering a realistic treatment plan. In general, secondary neutron dose was found to decrease as the distance to the treatment field increases and as the patient age increases. In addition, secondary neutron doses were studied as a function of the beam incidence. Next, neutron equivalent dose was assessed using organ-specific energy-dependent radiation weighting factors determined from Monte Carlo simulations of neutron spectra at each organ. The equivalent dose was found to reach a maximum value of ∼155 mSv at the level of the breasts for a delivery of 49 proton Gy to an intracranial tumour of a one-year-old female patient. Finally, a thorough comparison of the calculation results with published data demonstrated the dependence of neutron dose on the treatment configuration and proved the need for facility-specific and treatment-dependent neutron dose calculations.
Collapse
Affiliation(s)
- R Sayah
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN)-PRP-HOM/SDE-BP17, F-92262 Fontenay-aux-Roses Cedex, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Farah J, Martinetti F, Sayah R, Lacoste V, Donadille L, Trompier F, Nauraye C, Marzi LD, Vabre I, Delacroix S, Hérault J, Clairand I. Monte Carlo modeling of proton therapy installations: a global experimental method to validate secondary neutron dose calculations. Phys Med Biol 2014; 59:2747-65. [DOI: 10.1088/0031-9155/59/11/2747] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
34
|
Carnicer A, Angellier G, Thariat J, Sauerwein W, Caujolle JP, Hérault J. Quantification of dose perturbations induced by external and internal accessories in ocular proton therapy and evaluation of their dosimetric impact. Med Phys 2014; 40:061708. [PMID: 23718587 DOI: 10.1118/1.4807090] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Proton scattering on beam shaping devices and protons slowing down on media with different densities within the treatment volume may produce dose perturbations and range variations that are not predicted by treatment planning systems. The aim of this work was to assess the dosimetric impact of elements present in ocular proton therapy treatments that may disturb the prescribed treatment plan. Both distal beam shaping devices and intraocular elements were considered. METHODS A wedge filter, tantalum fiducial marker, hemispherical compensator, two intraocular endotamponades (densities 0.97 and 1.92 g cm(-3)) and an intraocular eye lens (IOL) were considered in the study. For these elements, longitudinal dose distributions were measured and∕or calculated in water in beam alignment for a clinical spread-out Bragg peak. Under the same conditions, the unperturbed dose distributions were similarly measured and∕or calculated in the absence of the element. The dosimetric impact was assessed by comparison of unperturbed and perturbed dose distributions. Measurements and calculations were carried out with two methods. Measurements are based on EBT3 films with dedicated software, which makes use of a calibration curve and correction for the quenching effect. Calculations are based on the Monte Carlo (MC) code MCNPX and reproduce the experimental conditions. Both dose maps are obtained with a resolution of 300 dpi. RESULTS The degree of disturbance of distal beam shaping devices is low for the wedge filter (2% overdose ripple all along the central axis) and moderate for the hemispherical compensator (two bands of variable overdose of up to 10% downstream the compensator lateral edges and -5% underdose on the plateau at off-axis distance of 5 cm). Tantalum clips produce important dose shadows (-20% behind the clip parallel to the beam and range reduction of 1.1 mm) and bands of overdose (15%). The presence of endotamponades modifies the dose distribution very significantly (-5% underdose on the plateau and 3 mm range prolongation for the tamponade with density 0.97 g cm(-3) and -15% underdose on plateau and 8 mm range reduction for that with density 1.92 g cm(-3)). No dose perturbations were found for the IOL. The high performance of EBT3 film and MC tools used was confirmed and good agreement was found between them (percentage of pixels passing the gamma test >87%). CONCLUSIONS The degree of disturbance by external beam shaping devices remains low in ocular proton therapy and can be reduced by bringing accessories closer to the eye. Tantalum fiducial markers must be located in such a way that dose perturbation is not projected on the tumor. The treatment of patients with intraocular endotamponades must be carefully managed. It is fundamental that radiation oncologists and medical physicists are informed about the presence of such substances prior to the treatment.
Collapse
Affiliation(s)
- A Carnicer
- Centre Antoine Lacassagne, Cyclotron Biomédical, 227 Avenue de la Lanterne, 06200 Nice, France
| | | | | | | | | | | |
Collapse
|
35
|
Farah J, Bonfrate A, De Oliveira A, Delacroix S, Hérault J, Martinetti F, Piau S, Trompier F, Vabre I, Clairand I. Test, validation and upgrade of the MD Anderson analytical model predicting secondary neutron radiation in proton therapy facilities. Phys Med 2014. [DOI: 10.1016/j.ejmp.2014.07.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
36
|
Bonfrate A, Farah J, De Marzi L, Delacroix S, Fontaine J, Hérault J, Sayah R, Trompier F, Lee C, Bolch W, Clairand I. Secondary doses to healthy tissues during proton therapy treatments: influence of irradiation parameters. Phys Med 2014. [DOI: 10.1016/j.ejmp.2014.07.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Carnicer A, Angellier G, Gérard A, Garnier N, Dubois C, Amblard R, Hérault J. Development and validation of radiochromic film dosimetry and Monte Carlo simulation tools for acquisition of absolute, high-spatial resolution longitudinal dose distributions in ocular proton therapy. RADIAT MEAS 2013. [DOI: 10.1016/j.radmeas.2013.06.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Thariat J, Lanza F, Peyrichon M, Barnel C, Angellier G, Caujolle J, Moschi C, Hérault J. Protonthérapie des mélanomes uvéaux avec atteinte papillaire : pertinence d’une épargne maculaire ? Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Carnicer A, Letellier V, Rucka G, Angellier G, Sauerwein W, Hérault J. Study of the secondary neutral radiation in proton therapy: Toward an indirectin vivodosimetry. Med Phys 2012; 39:7303-16. [DOI: 10.1118/1.4765049] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
40
|
Doyen J, Poudenx M, Eriksson P, Otto J, Venissac N, Angellier G, Hérault J, Bondiau PY. Étude de phase I sur l’ajout d’une radiothérapie ablative dans le cancer bronchique non à petites cellules de stade III : résultats préliminaires. Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Mosci C, Lanza FB, Barla A, Mosci S, Hérault J, Anselmi L, Truini M. Comparison of Clinical Outcomes for Patients with Large Choroidal Melanoma after Primary Treatment with Enucleation or Proton Beam Radiotherapy. Ophthalmologica 2012; 227:190-6. [DOI: 10.1159/000334401] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Accepted: 10/01/2011] [Indexed: 11/19/2022]
|
42
|
|
43
|
De Nardo L, Colautti P, Hérault J, Conte V, Moro D. Microdosimetric characterisation of a therapeutic proton beam used for conjunctival melanoma treatments. RADIAT MEAS 2010. [DOI: 10.1016/j.radmeas.2010.05.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
44
|
|
45
|
Bondiau PY, Thariat J, Bénézery K, Hérault J, Dalmasso C, Marcié S, Malandain G. Doses auxorganes àrisque cérébraux: optimisation parradiothérapie stéréotaxique robotisée etatlas desegmentation automatique versus radiothérapie conformationnelle tridimensionnelle. Cancer Radiother 2007. [DOI: 10.1016/j.canrad.2007.09.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
46
|
Abstract
The aim of this work was to study the dosimetric potential of the Monte Carlo code MCNPX applied to the protontherapy field. For series of clinical configurations a comparison between simulated and experimental data was carried out, using the proton beam line of the MEDICYC isochronous cyclotron installed in the Centre Antoine Lacassagne in Nice. The dosimetric quantities tested were depth-dose distributions, output factors, and monitor units. For each parameter, the simulation reproduced accurately the experiment, which attests the quality of the choices made both in the geometrical description and in the physics parameters for beam definition. These encouraging results enable us today to consider a simplification of quality control measurements in the future. Monitor Units calculation is planned to be carried out with preestablished Monte Carlo simulation data. The measurement, which was until now our main patient dose calibration system, will be progressively replaced by computation based on the MCNPX code. This determination of Monitor Units will be controlled by an independent semi-empirical calculation.
Collapse
Affiliation(s)
- J Hérault
- Centre Antoine Lacassagne, Cyclotron Biomedical, 227 avenue de la Lanterne, 06200 Nice, France.
| | | | | | | |
Collapse
|
47
|
Bensadoun R, Marcié S, Ortholan C, Serrano B, Dalmasso C, Bénézerv K, Hérault J, Madelis G, Demonchy M, Gérard J. Parotid gland sparing with step-and-shoot intensity modulated radiation in nasopharyngeal and oropharyngeal tumors. 3 years experience at the centre antoine-lacassagne. Radiother Oncol 2007. [DOI: 10.1016/s0167-8140(07)80063-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Delion S, Chalon S, Hérault J, Guilloteau D, Besnard JC, Durand G. Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. J Nutr 2006; 124:2466-76. [PMID: 16856329 DOI: 10.1093/jn/124.12.466] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
This study examined the effects of dietary alpha-linolenic acid [18:3(n-3)] deficiency on dopaminergic serotoninergic neurotransmission systems in 60-d-old male rats. Rats were fed semipurified diets containing either peanut oil [the (n-3)-deficient group] or peanut plus rapeseed oil (control group). We measured the densities of the serotonin-2 (5-HT2) receptors and the dopamine-2 (D2) receptors by autoradiography and membrane-binding assays in relation to the fatty acid composition and levels of endogenous monoamines in three cerebral regions: the frontal cortex, the striatum and the cerebellum. Long-term feeding of the (n-3)-deficient diet induced a significantly higher 5-HT2 receptor density in the frontal cortex compared with the control rats without any difference in the endogenous serotonin concentrations. The results also showed some modification of dopaminergic neurotransmission specifically in the frontal cortex in the rats deficient in alpha-linolenic acid, with a significantly lower density of D2 receptors and a significantly lower concentration of endogenous dopamine than in control animals. Moreover, there were lower levels of (n-3) fatty acids in all the regions studied in the deficient rats, balanced by greater levels of (n-6) fatty acids. These results suggest that chronic consumption of an alpha-linolenic acid-deficient diet could induce modifications of the neurotransmission pathways; this might induce the behavioral disturbances previously described in this fatty acid-deficient animal model.
Collapse
Affiliation(s)
- S Delion
- INSERM U 316, Laboratoire de Biophysique Médicale et Pharmaceutique et Laboratoire de Biochimie, 37200 Tours Cedex, France
| | | | | | | | | | | |
Collapse
|
49
|
Serrano B, Hachem A, Franchisseur E, Hérault J, Marcié S, Costa A, Bensadoun RJ, Barthe J, Gérard JP. Monte Carlo simulation of a medical linear accelerator for radiotherapy use. Radiat Prot Dosimetry 2006; 119:506-9. [PMID: 16644964 DOI: 10.1093/rpd/nci620] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
A Monte Carlo code MCNPX (Monte Carlo N-particle) was used to model a 25 MV photon beam from a PRIMUS (KD2-Siemens) medical linear electron accelerator at the Centre Antoine Lacassagne in Nice. The entire geometry including the accelerator head and the water phantom was simulated to calculate the dose profile and the relative depth-dose distribution. The measurements were done using an ionisation chamber in water for different square field ranges. The first results show that the mean electron beam energy is not 19 MeV as mentioned by Siemens. The adjustment between the Monte Carlo calculated and measured data is obtained when the mean electron beam energy is approximately 15 MeV. These encouraging results will permit to check calculation data given by the treatment planning system, especially for small fields in high gradient heterogeneous zones, typical for intensity modulated radiation therapy technique.
Collapse
Affiliation(s)
- B Serrano
- LPES-CRESA, Laboratoire de Physique Electronique des Solides, Centre de Recherche sur les Solides et leurs Applications, EA1174, Université de Nice-Sophia Antipolis, Parc Valrose, 06108 Nice cedex 2, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Patients with ocular melanoma have been treated since June 1991 at the medical cyclotron of the Centre Antoine Lacassagne (CAL). Positions and sizes of the ocular nozzle elements were initially defined based on experimental work, taking as a pattern functional existing facilities. Nowadays Monte Carlo (MC) calculation offers a tool to refine this geometry by adjusting size and place of beam modeling devices. Moreover, the MC tool is a useful way to calculate the dose and to evaluate the impact of secondary particles in the field of radiotherapy or radiation protection. Both LINAC and cyclotron producing x rays, electrons, protons, and neutrons are available in CAL, which suggests choosing MCNPX for its particle versatility. As a first step, the existing installation was input in MCNPX to check its aptitude to reproduce experimentally measured depth-dose profile, lateral profile, output-factor (OF), and absolute dose. The geometry was defined precisely and described from the last achromatic bending magnet of our proton beam line to the position of treated eyes. Relative comparisons of percentage depth-dose and lateral profiles, performed between measured data and simulations, show an agreement of the order of 2% in dose and 0.1 mm in range accuracy. These comparisons, carried out with and without beam-modifying device, yield results compatible to the required precision in ocular melanoma treatments, as long as adequate choices are made on MCNPX input decks for physics card. Absolute dose and OF issued from calculations and measurements were also compared. Results obtained for these two kinds of data, carried out in the simplified situation of an unmodulated beam, indicate that MC calculation could effectively complement measurements. These encouraging results are a large source of motivation to promote further studies, first in a new design of the ocular nozzle, and second in the analysis of the influence of beam-modifying devices attached to the final patient collimator, such as wedge or compensators, on dose values.
Collapse
Affiliation(s)
- J Hérault
- Centre Antoine Lacassagne, Cyclotron Biomedical, 227 Avenue de la Lanterne, 06200 Nice, France.
| | | | | | | |
Collapse
|